Efficacy and Safety of ALT-801 in the Treatment of Obesity
Study sponsor: Altimmune, Inc. · ALT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-28Actual
Enrollment · participants391Actual
Source updated2023-11-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.